Beijing Xinyi Biotechnology

Founded in 2015 by Wenjun Yang, Beijing Xinyi Biotechnology, which operates as TargetingOne, is a high-tech enterprise situated in Beijing's Zhongguancun Science and Technology Park. The firm concentrates on the independent development of molecular diagnostic technology, particularly digital PCR (dPCR), and its application to major diseases. TargetingOne has experienced rapid development, applying for over 200 patents and receiving more than 150.

The company's business revolves around the manufacturing of micro-droplet digital PCR instruments and in-vitro diagnostic reagents. Its product portfolio includes a range of PCR instruments, reagents, and sample extraction tools. These products provide a technical method for the research and diagnosis of tumors, genetic diseases, and infectious diseases. TargetingOne's clients are in the life sciences, precision medicine, drug development, and health management sectors. The business model is centered on developing and selling these advanced molecular diagnostic systems and reagents.

TargetingOne offers a suite of products based on its proprietary dPCR technology. This includes the D30 and D50 Automatic Digital PCR Systems, which are designed for high-throughput, automated analysis. The company also produces various detection kits for specific applications, such as the Human EGFR Gene Mutation Detection Kit for lung cancer liquid biopsies and a Hepatitis B DNA Quantitative Detection Digital PCR Reagent. A key feature of their dPCR technology is its high sensitivity and accuracy, which allows for absolute quantification of nucleic acids without reliance on standard curves, a limitation of traditional qPCR methods. This makes it particularly effective for detecting rare mutations and pathogens in low concentrations. The company's dPCR testing kit for SARS-CoV-2 was the first of its kind to receive a Class III medical device registration certificate from China's NMPA.

Significant milestones include raising a total of $23.2 million over three funding rounds, with a notable Series B round in January 2021 led by Lilly Asia Ventures. The latest funding was a Series B round on February 25, 2024, led by Jiuzhi Capital. The company has received numerous accolades, including the Gold Award of China In Vitro Diagnostic Excellent Innovation Product for two consecutive years. Its products have also gained international recognition, with CE market approval in the European Union for its novel coronavirus nucleic acid testing products.

Keywords: molecular diagnostics, digital PCR, dPCR, in-vitro diagnostics, precision medicine, life sciences, genetic testing, liquid biopsy, infectious disease detection, cancer diagnostics, nucleic acid testing, diagnostic reagents, lab automation, Beijing Xinyi Biotechnology, Zhongguancun, Wenjun Yang, medical devices, high-throughput screening, CE mark, NMPA approved